Interim report
Page 1
Date: February 05, 2026 To, BSE Limited, 20th Floor, P.J. Towers, Dalal Street, Mumbai - 400001. BSE Scrip Code: 544449 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: ANTHEM Subject: Outcome of the Board Meeting held on Thursday, February 05, 2026 Dear Sir/Ma’am Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), we would like to inform you that the Board of Directors of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) ("Company") at their meeting held on Thursday, February 05, 2026 which commenced at 11:40 a.m. and concluded at 12.55 p.m. have inter-alia, approved the following matters: 1. Unaudited Financial Results The Board of Directors (Board) have approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of Statutory Auditors for the quarter and nine months ended December 31, 2025. The said financials results for the quarter and nine months ended December 31, 2025 were duly reviewed and recommended by Audit Committee at its meeting held on same day to the Board. A copy of the said Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Statutory Auditors are enclosed herewith and the extract of the results will be published in the newspapers as required under Regulation 47(1) of SEBI LODR Regulations. 2. Allotment of Equity Shares pursuant to Anthem Employee Stock Option Plan 2024 The Board have approved allotment of 1,03,800 Equity Shares of face value of Rs. 2 (Rupees two only) each to the eligible employees of the Company upon exercise of the Options vested with them under the Anthem Employee Stock Option Plan 2024. Consequent to this allotment, the paid-up equity share capital of the Company stand increased from Rs. 1,12,32,20,102/- (consisting of 56,16,10,051 equity shares of face value of Rs. 2 each) to Rs. 1,12,34,27,702/- (consisting of 56,17,13,851 equity shares of face value of Rs. 2 each).
Page 2
The details as required under the Regulation 10(c) SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are as follows: Sl No Particulars Disclosure - ESOP 2024 1 Company Name and Address of Registered Office Anthem Biosciences Limited No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase I, Bangalore, Karnataka, India, 560099 2 Name of the Stock Exchanges on which the Company’s shares are listed BSE Limited (BSE) Nation al Stock Exchange of India Limited (NSE) 3 Filing date of the statement referred in regulation 10(b) of the SEBI ( SBEB) Regulations, with Stock Exchange November 03, 2025 4 Filing Number, if any BSE: DCS/ESOP/IP/RG/3935/2025-26 NSE: NSE/LIST/51770 5 Title of the Scheme pursuant to which shares are issued Anthem Employee Stock Option Plan 2024 6 Kind of security to be listed Equity Shares 7 Par value of the shares Rs. 2/- 8 Number of shares issued 1,03,800 9 Share Certificate No., if applicable Not Applicable 10 Distinctive number of the shares, if applicable 573019752 - 573123551 11 ISIN Number of the shares if issued in Demat INE0CZ201020 12 Exercise price per share Rs.100.75 13 Premium per share Rs. 98.75 14 Total Issued shares after this issue 56,17,13,851
Page 3
15 Total Issued share capital after this issue Rs. 1,12,34,27,702 16 Details of any lock-in on the shares Not Applicable 17 Date of expiry of lock-in Not Applicable 18 Whether shares identical in all respects to existing shares if not, when will they become identical? All equity shares of the Company allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company. 19 Details of listing fees, if payable Not Applicable The above intimation is also available on the Company’s website at https://www.anthembio.com/investors/ We request you to kindly take the same on record. Thanking you, Yours truly, For Anthem Biosciences Limited (Formerly known as Anthem Biosciences Private Limited) _____________________ Divya Prasad Company Secretary & Compliance Officer Membership No: A41438 DIVYA PRASAD Digitally signed by DIVYA PRASAD Date: 2026.02.05 13:07:22 +05'30'
Page 4
K.P.RAO & CO. ’Poornima’, II Floor, 25, State Bank Road CHARTERED ACCOUNTANTS Bangalore - 560 001. Karnataka, India K.P.RAO K.VISWANATH Phone: 0825587385,25586814 H.N.ANIL S.PRASHANTH Fax: 25594661 MOHAN.R.LAVI P.RAVINDRANATH E Mail: info@kprao.co.in Branches Hyderabad: 3rd floor, D1, 6-3-652, Kautilya, Somajiguda, Hyderabad – 500 082. Ph.: 040-23322310 Independent Auditor's Review Report on the quarterly and year to date Unaudited Standalone Financial results of Anthem Biosciences Limited pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) Review report to The Board of Directors of Anthem Biosciences Limited Bangalore 1. We have reviewed the Unaudited Standalone Financial result of Anthem Biosciences Limited (the "Company"), included in the accompanying "Statement of Unaudited Consolidated and Standalone Financial results for the quarter and nine months ended December 31, 2025 (the Statement) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations). 2. The Company’s management is responsible for the preparation of the Statement, in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (“SRE”) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of In dia (“ICAI”). A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Page 5
K.P.RAO & CO. Chartered Accountants Continuation Sheet… Branches Hyderabad: 3rd floor, D1, 6-3-652, Kautilya, Somajiguda, Hyderabad – 500 082. Ph.: 040-23322310 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For K. P. Rao & Co., Chartered Accountants FRN: 003135S Mohan R Lavi Partner Membership No. 029340 Place: Bangalore Date: 5th February 2026 UDIN: 26029340MQGTDT9002 Raghothama Mohan Lavi Digitally signed by Raghothama Mohan Lavi Date: 2026.02.05 12:58:46 +05'30'
Page 6
Rs in Mn Year End 31/12/2025 30/09/2025 31/12/2024 31/12/2025 31/12/2024 31/03/2025 Unaudited Unaudited Unaudited (Note 4) Unaudited Unaudited (Note 6) Audited Income: Revenue from operations 4,165.75 5,522.26 4,982.62 15,068.12 13,616.65 18,406.49 Other income 399.22 537.99 243.35 1,214.50 716.21 1,094.40 Total income 4,564.98 6,060.25 5,225.97 16,282.61 14,332.86 19,500.89 Expenses: Cost of materials consumed 1,805.71 2,037.12 2,545.73 5,466.78 6,458.11 8,280.79 Changes in inventories of finished goods, work-in-progress and stock in trade (423.33) 220.98 (224.21) 484.37 (799.87) (867.05) Employee benefit expenses 654.71 631.58 546.51 1,971.99 1,957.42 2,521.67 Finance cost 11.27 22.32 17.86 49.65 69.86 90.89 Depreciation and amortisation expense 267.48 239.20 195.02 732.81 569.48 779.37 Other expenses 498.20 376.03 446.02 1,303.68 1,092.01 1,580.97 Total expenses 2,814.04 3,527.23 3,526.92 10,009.28 9,347.01 12,386.66 Profit before exceptional items and tax 1,750.94 2,533.02 1,699.05 6,273.33 4,985.85 7,114.23 Exceptional items (Note 7) 249.84 - - 249.84 - - Profit before tax 1,501.10 2,533.02 1,699.05 6,023.49 4,985.85 7,114.23 Tax expense Current tax 377.80 637.51 427.62 1,515.99 1,254.84 1,820.27 Deferred tax 2.05 (88.83) (8.49) (81.49) (105.24) 232.08 Total tax expenses 379.84 548.68 419.12 1,434.51 1,149.60 2,052.36 Profit for the Period/Year 1,121.25 1,984.34 1,279.93 4,588.98 3,836.25 5,061.88 Other comprehensive income Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period (9.80) (19.39) (2.33) (9.11) (7.36) (5.30) Income tax on above 2.47 4.88 0.59 2.29 1.85 1.33 Other comprehensive income/(loss) for the period/year (7.33) (14.51) (1.74) (6.82) (5.50) (3.96) Total comprehensive income for the period/year 1,113.92 1,969.83 1,278.19 4,582.17 3,830.74 5,057.91 Paid-up equity share capital (face value of Rs.2 each) 1,123.22 1,123.22 1,118.15 1,123.22 1,118.15 1,118.15 Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity' 23,613.97 Earnings per share (not annualised) Basic 2.00 3.54 2.29 8.18 6.86 9.05 Diluted 1.98 3.50 2.28 8.09 6.83 9.01 See accompaning notes to financial results STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED AND PERIOD ENDED DECEMBER 31, 2025 Particulars Quarter ended ANTHEM BIOSCIENCES LIMITED CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703 REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099. KARNATAKA INDIA. Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com Year to date
Page 7
Notes to Standalone Financial Statements 1 2 3 4 5 6 7 8 Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year. Anthem Biosciences Limited CIN:L24233KA2006PLC039703 Ajay Bhardwaj Managing Director DIN: 00333704 Place: Bangalore Date: February 05, 2026 During the year, the company has allotted 2,532,951 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on June 11, 2025. For and on behalf of the board of directors of These unaudited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations") . The above statement of unaudited standalone financial results ("the Statements") of the Company for the quarter ended and period ended 31st December 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 5, 2026. These statements have been subjected to review by the Statutory Auditor of the Company. The reports of the Statutory Auditor are unqualified. The Company has completed its IPO of Offer for Sale equity shares of face value of Rs. 2/- each at an issue price of Rs. 570/- per equity share, comprising offer for sale of 59,575,319 shares by selling share holders. The equity shares of the company were listed on NSE Limited and BSE Limited on July 21, 2025. On July 21, 2025, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Accordingly, comparative numbers for the quarter ended December 31, 2024 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company. The standalone financial information for the nine months ended December 31, 2024 has been extracted from the unaudited Financial Statements. On November 21, 2025, the Government of India notified four new Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs in this regard. The Company has assessed and made a provision, as an Exceptional Item consistent with the guidance provided by the Institute of Chartered Accountants of India, in the standalone financial results for the quarter and nine months ended December 31, 2025. The Company will continue to monitor the finalization of Central / State Rules and clarifications from the Government on other aspects of the new Labour Code and will take necessary steps to ensure compliance thereof and also provide appropriate accounting effects, as needed.
Page 8
K.P.RAO & CO. ’Poornima’, II Floor, 25, State Bank Road CHARTERED ACCOUNTANTS Bangalore - 560 001. Karnataka, India K.P.RAO K.VISWANATH Phone: 0825587385,25586814 H.N.ANIL S.PRASHANTH Fax: 25594661 MOHAN.R.LAVI P.RAVINDRANATH E Mail: info@kprao.co.in Branches Hyderabad: 3rd floor, D1, 6-3-652, Kautilya, Somajiguda, Hyderabad – 500 082. Ph.: 040-23322310 Independent Auditor's Review Report on the quarterly and year to date Unaudited Consolidated Financial Results of Anthem Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) Review report to The Board of Directors of Anthem Biosciences Limited Bangalore 1. We have reviewed the Unaudited Consolidated Financial Results of Anthem Biosciences Limited (the "Company") and its subsidiary (the Company and its subsidiary together referred to as "the Group"), included in the accompanying "Statement of Unaudited Consolidated and Standalone Financial results for the quarter and nine months ended December 31, 2025, (the Statement) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations). 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (“SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Page 9
K.P.RAO & CO. Chartered Accountants Continuation Sheet… Branches Hyderabad: 3rd floor, D1, 6-3-652, Kautilya, Somajiguda, Hyderabad – 500 082. Ph.: 040-23322310 We also performed procedures in accordance with the Circulars issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, as amended to the extent applicable. The Statement includes the results of Neoanthem Lifesciences Private Limited (a wholly owned subsidiary). 4. The Statement includes the unaudited financial results of one subsidiary, Neoanthem Lifesciences Private Limited , whose financial statements reflect total revenue (before consolidation adjustments) of Rs. 299.15 million and total net loss (before consolidation adjustments) of Rs. 568.16 million and total comprehensive loss (net) of Rs. 569.33 million for the quarter ended on that date, as considered in the Statement, which have been reviewed by us. Our opinion on the Statement is not modified in respect of the above matters. 5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For K. P. Rao & Co., Chartered Accountants FRN: 003135S Mohan R Lavi Partner Membership No. 029340 Place: Bangalore Date: 5th February 2026 UDIN: 26029340WQYDTO5220 Raghothama Mohan Lavi Digitally signed by Raghothama Mohan Lavi Date: 2026.02.05 13:00:02 +05'30'
Page 10
Rs in Mn Year End 31/12/2025 30/09/2025 31/12/2024 31/12/2025 31/12/2024 31/03/2025 Unaudited Unaudited Unaudited (Note 4) Unaudited Unaudited (Note 6) Audited Income: Revenue from operations 4,231.53 5,500.27 4,978.06 15,133.89 13,613.56 18,445.53 Other income 335.30 482.29 243.70 1,045.71 716.70 857.32 Total income 4,566.83 5,982.56 5,221.77 16,179.60 14,330.26 19,302.85 Expenses: Cost of materials consumed 1,849.22 2,012.63 2,551.27 5,483.90 6,470.53 8,306.17 Changes in inventories of finished goods, work-in-progress and stock in trade (423.33) 220.98 (224.21) 484.37 (799.87) (867.05) Employee benefit expenses 704.79 677.16 568.71 2,102.28 2,007.16 2,604.94 Finance cost 3.52 30.31 25.52 49.94 98.08 103.29 Depreciation and amortisation expense 345.33 334.99 202.79 944.79 589.49 893.71 Other expenses 528.85 410.47 487.20 1,397.39 1,179.31 1,693.11 Total expenses 3,008.39 3,686.53 3,611.29 10,462.66 9,544.70 12,734.17 Profit before exceptional items and tax 1,558.44 2,296.03 1,610.48 5,716.94 4,785.56 6,568.68 Exceptional items (Note 8) 253.71 - - 253.71 - - Profit before tax 1,304.74 2,296.03 1,610.48 5,463.23 4,785.56 6,568.68 Tax expense Current tax 377.80 637.51 377.21 1,515.99 1,204.43 1,820.27 Deferred tax (1.23) (75.77) (10.04) (73.10) (105.24) 235.81 Total tax expenses 376.57 561.74 367.17 1,442.89 1,099.19 2,056.08 Profit for the Period/Year 928.17 1,734.28 1,243.31 4,020.34 3,686.37 4,512.60 Other comprehensive income Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period (10.64) (20.28) (2.51) (10.53) (7.36) (5.30) Income tax on above 2.85 4.82 0.63 2.54 1.85 1.33 Other comprehensive income/(loss) for the period/year (7.80) (15.46) (1.88) (7.99) (5.50) (3.96) Total comprehensive income for the period/year 920.37 1,718.82 1,241.43 4,012.35 3,680.87 4,508.63 Paid-up equity share capital (face value of Rs.2 each) 1,123.22 1,123.22 1,118.15 1,123.22 1,118.15 1,118.15 Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity' 22,980.48 Non-controlling interests Earnings per share (not annualised for the Quarter) Basic 1.65 3.09 2.22 7.17 6.59 8.07 Diluted 1.64 3.06 2.21 7.09 6.56 8.04 See accompaning notes to financial results STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED AND PERIOD ENDED DECEMBER 31, 2025 Particulars Quarter ended ANTHEM BIOSCIENCES LIMITED CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703 REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099. KARNATAKA INDIA. Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com Year to date
Page 11
Notes to Consolidated Financial Statements 1 2 3 4 5 6 7 The consolidated financial statements include the financial results of Anthem Biosciences Limited (Parent Company) and of the following subsidiaries: Neoanthem Lifesciences Private limited (wholly owned subsidiary) 8 9 Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year. Anthem Biosciences Limited CIN:L24233KA2006PLC039703 Ajay Bhardwaj Managing Director DIN: 00333704 Place: Bangalore Date: February 05, 2026 During the year, the company has allotted 2,532,951 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on June 11, 2025 For and on behalf of the board of directors of These unaudited consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations") . The above statement of unaudited consolidated financial results ("the Statements") of the Company for the quarter ended and period year ended 31st December 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 5th February 2026. These statements have been subjected to review by the Statutory Auditor of the Company. The reports of the Statutory Auditor are unqualified. The Company has completed its IPO of Offer for Sale of equity shares of face value of Rs. 2/- each at an issue price of Rs. 570/- per equity share, comprising offer for sale of 59,575,319 shares by selling share holders. The equity shares of the company were listed on NSE Limited and BSE Limited on July 21, 2025. On July 21, 2025 the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Accordingly, comparative numbers for the quarter ended December 31, 2024 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company. The consolidated financial information for the nine months ended December 31, 2024 has been extracted from the unaudited Financial Statements. On November 21, 2025, the Government of India notified four new Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs in this regard. The Company has assessed and made a provision, as an Exceptional Item consistent with the guidance provided by the Institute of Chartered Accountants of India, in the consolidated financial results for the quarter and nine months ended December 31, 2025. The Company will continue to monitor the finalization of Central / State Rules and clarifications from the Government on other aspects of the new Labour Code and will take necessary steps to ensure compliance thereof and also provide appropriate accounting effects, as needed.
Page 12
Anthem Biosciences Limited Year Ended 31/12/2025 30/09/2025 31/12/2024 31/12/2025 31/12/2024 31/03/2025 [Unaudited] [Unaudited] [Unaudited] (Note 4) [Unaudited] [Unaudited] (Note 6) [Audited] I Segment wise revenue and results: Segment revenue: a)CRDMO 3,332.39 4,718.89 4,135.21 12,599.32 11,138.12 15,060.93 b)Speciality Ingredients 899.14 781.38 842.85 2,534.57 2,475.44 3,384.60 Total 4,231.53 5,500.27 4,978.06 15,133.89 13,613.56 18,445.53 II Segmental Results: Gross profits from each segment a)CRDMO 2,347.93 2,885.21 2,219.61 7,891.55 6,694.38 9,303.31 b)Speciality Ingredients 457.70 381.45 431.38 1,274.07 1,248.52 1,703.10 Total 2,805.63 3,266.67 2,650.99 9,165.62 7,942.90 11,006.40 Less: Selling and un-allocable expenditure net of other income 1,500.89 970.64 1,040.52 3,702.39 3,157.34 4,437.73 Total profit before tax: 1,304.74 2,296.02 1,610.47 5,463.23 4,785.56 6,568.68 CONSOLIDATED SEGMENT INFORMATION Amount (INR Mn) Sl.No Particulars Quarter Ended Year to date